The FDA is reconsidering its approval of an experimental drug developed by ChemoCentryx for a rare autoimmune disease. Released in May 2021, the FDA's briefing document highlighted concerns about the drug's effectiveness compared to existing therapies. While some patients and doctors see potential benefits, the FDA pointed out difficulties in interpreting study results due to design flaws. The outcome of this review could impact treatment options for patients reliant on steroids.
Key facts
- FDA released a briefing document in May 2021 regarding an experimental drug.
- The drug is intended for a rare autoimmune form of vasculitis.
- Study participants showed slightly higher symptom remission rates after one year.
- FDA noted challenges in interpreting study results due to design issues.
- Some patients and physicians believe the drug could reduce reliance on steroids.
A short AI summary in our own words. The reporting belongs to Ars Technica; we don't reproduce it.